Article
Antiretroviral activity and safety of abacavir in combination with selected HIV-1 protease inhibitors in therapy-naive HIV-1-infected adults.
Antiviral therapy - 1 Jun 2001
McMahon D, Lederman M, Haas D W, Haubrich R, Stanford J, Cooney E, Horton J, Kelleher D, Ross L, Cutrell A, Lee D, Spreen W, Mellors J W
Abstract excerpt
OBJECTIVE: To assess antiretroviral efficacy and safety of abacavir in combination with selected HIV-1 protease inhibitors. DESIGN: A 48-week, open-label study. MATERIALS AND METHODS: Eighty-two antiretroviral naive HIV-1-infected adults (CD4 cell count > or = 100 cells/mm3, plasma HIV-1 RNA > or = 5,000 copies/ml) were randomly assigned to receive abacavir (300 mg twice daily) in combination with standard doses...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.